Sarepta Therapeutics, Inc. SRPT, a developer of innovative RNA-targeted therapeutics, today announced the publication of results from a multiple ascending dose study to determine the safety of AVI-7288, a PMO plus ® antisense oligonucleotide, in healthy adult volunteers, in the July 23, 2015 issue of The New England Journal of Medicine. The results of the study, conducted in collaboration with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), demonstrated no clinical or toxicologic safety concerns with AVI-7288, an investigational treatment for Marburg Virus (MARV) infection.